Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up
Chronic low-grade inflammation, commonly associated with cardiovascular diseases and risk factors, has been associated inconclusively with cognitive decline and dementia. The aim of our study was to evaluate whether low-grade inflammation, measured in midlife, is associated with a decline in cogniti...
Gespeichert in:
Veröffentlicht in: | Neurology 2022-11, Vol.99 (20), p.e2294-e2302 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e2302 |
---|---|
container_issue | 20 |
container_start_page | e2294 |
container_title | Neurology |
container_volume | 99 |
creator | Kipinoinen, Teemu Toppala, Sini Rinne, Juha O. Viitanen, Matti H. Jula, Antti M. Ekblad, Laura L. |
description | Chronic low-grade inflammation, commonly associated with cardiovascular diseases and risk factors, has been associated inconclusively with cognitive decline and dementia. The aim of our study was to evaluate whether low-grade inflammation, measured in midlife, is associated with a decline in cognitive performance after a 10-year follow-up. We hypothesized that low-grade inflammation, estimated by interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and high-sensitivity CRP (hs-CRP), is a predictor of cognitive decline in the general population.
This prospective cohort study is based on a Finnish nationwide, population-based Health 2000 Examination Survey, its supplemental examinations in 2000-2001, and the follow-up Health 2011 Survey. Cognitive performance at baseline and at follow-up was assessed with categorical verbal fluency (VF), word-list learning (WLL), and word-list delayed recall (WLDR). Baseline low-grade inflammation was measured with IL-6, TNF-α, and hs-CRP in 2001. Associations between low-grade inflammation and cognitive performance were analyzed with multivariable linear models adjusted for age, sex, education,
genotype, type 2 diabetes, hypertension, hypercholesterolemia, body mass index, depressive symptoms, smoking, and baseline cognition.
Nine hundred fifteen participants aged 45-74 years (median age 54 years, 55% women) were included in the analysis. Both higher IL-6 and TNF-α at baseline predicted poorer performance in VF and WLL at 10-year follow-up (VF: IL-6 β: -1.14,
= 0.003, TNF-α β: -1.78,
= 0.008; WLL: IL-6 β: -0.61,
= 0.007, TNF-α β: -0.86,
= 0.03). Elevated IL-6 also predicted a greater decline in VF and WLL after a 10-year follow-up (VF: β: -0.81,
= 0.01; WLL: β: -0.53,
= 0.008). Baseline TNF-α did not predict cognitive decline, and hs-CRP did not predict cognitive performance or decline after 10-years.
Our results suggest that low-grade inflammation in midlife is an independent risk factor for poorer cognitive performance later in life. Of the studied markers, IL-6 and TNF-α seem to be stronger predictors for cognitive performance and decline than hs-CRP. |
doi_str_mv | 10.1212/WNL.0000000000201116 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2721637757</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2721637757</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4493-57690253957cc6115cee067ed65bbc789b6e3fe769707a531ed0e989918ef9043</originalsourceid><addsrcrecordid>eNpdkE1PGzEQhi3UqgTaf4AqH3sx9cfaXh9R1ABSQjlQBcRh5TizjYt3HexdIv49pnxU6lxGmnnfdzQPQkeMHjPO-PflxfyYvhenjDG1hyZMckWU4Ncf0KSMayJqXe-jg5z_UFqW2nxC-0IxI6uqnqDbk5yj83bwscexxQu_Dr4FfN63wXadHWJ6xAub7iBlvPTDBk_j794P_gHwJaQ2ps72DrAdMKPkBmzCsxhC3JFx-xl9bG3I8OW1H6Jfsx9X0zMy_3l6Pj2ZE1dVRhCplaFcCiO1c4ox6QCo0rBWcrVyujYrBaKFotJUWykYrCmY2hhWQ2toJQ7Rt5fcbYr3I-Sh6Xx2EILtIY654ZozJbSWukirF6lLMecEbbNNvrPpsWG0ecbaFKzN_1iL7evrhXHVwfrd9MbxX-4uhqGgugvjDlKzARuGzd-88lhFOOW8BEpKyoQJ8QRP9YE6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2721637757</pqid></control><display><type>article</type><title>Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Kipinoinen, Teemu ; Toppala, Sini ; Rinne, Juha O. ; Viitanen, Matti H. ; Jula, Antti M. ; Ekblad, Laura L.</creator><creatorcontrib>Kipinoinen, Teemu ; Toppala, Sini ; Rinne, Juha O. ; Viitanen, Matti H. ; Jula, Antti M. ; Ekblad, Laura L.</creatorcontrib><description>Chronic low-grade inflammation, commonly associated with cardiovascular diseases and risk factors, has been associated inconclusively with cognitive decline and dementia. The aim of our study was to evaluate whether low-grade inflammation, measured in midlife, is associated with a decline in cognitive performance after a 10-year follow-up. We hypothesized that low-grade inflammation, estimated by interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and high-sensitivity CRP (hs-CRP), is a predictor of cognitive decline in the general population.
This prospective cohort study is based on a Finnish nationwide, population-based Health 2000 Examination Survey, its supplemental examinations in 2000-2001, and the follow-up Health 2011 Survey. Cognitive performance at baseline and at follow-up was assessed with categorical verbal fluency (VF), word-list learning (WLL), and word-list delayed recall (WLDR). Baseline low-grade inflammation was measured with IL-6, TNF-α, and hs-CRP in 2001. Associations between low-grade inflammation and cognitive performance were analyzed with multivariable linear models adjusted for age, sex, education,
genotype, type 2 diabetes, hypertension, hypercholesterolemia, body mass index, depressive symptoms, smoking, and baseline cognition.
Nine hundred fifteen participants aged 45-74 years (median age 54 years, 55% women) were included in the analysis. Both higher IL-6 and TNF-α at baseline predicted poorer performance in VF and WLL at 10-year follow-up (VF: IL-6 β: -1.14,
= 0.003, TNF-α β: -1.78,
= 0.008; WLL: IL-6 β: -0.61,
= 0.007, TNF-α β: -0.86,
= 0.03). Elevated IL-6 also predicted a greater decline in VF and WLL after a 10-year follow-up (VF: β: -0.81,
= 0.01; WLL: β: -0.53,
= 0.008). Baseline TNF-α did not predict cognitive decline, and hs-CRP did not predict cognitive performance or decline after 10-years.
Our results suggest that low-grade inflammation in midlife is an independent risk factor for poorer cognitive performance later in life. Of the studied markers, IL-6 and TNF-α seem to be stronger predictors for cognitive performance and decline than hs-CRP.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000201116</identifier><identifier>PMID: 36195448</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Biomarkers ; C-Reactive Protein ; Cognition ; Diabetes Mellitus, Type 2 ; Female ; Follow-Up Studies ; Humans ; Inflammation ; Interleukin-6 ; Male ; Middle Aged ; Prospective Studies ; Tumor Necrosis Factor-alpha</subject><ispartof>Neurology, 2022-11, Vol.99 (20), p.e2294-e2302</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4493-57690253957cc6115cee067ed65bbc789b6e3fe769707a531ed0e989918ef9043</citedby><cites>FETCH-LOGICAL-c4493-57690253957cc6115cee067ed65bbc789b6e3fe769707a531ed0e989918ef9043</cites><orcidid>0000-0001-6369-0764 ; 0000-0001-5760-5367 ; 0000-0002-5863-8088 ; 0000-0002-3522-5301 ; 0000-0002-4506-9584 ; 0000-0002-0037-1587</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36195448$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kipinoinen, Teemu</creatorcontrib><creatorcontrib>Toppala, Sini</creatorcontrib><creatorcontrib>Rinne, Juha O.</creatorcontrib><creatorcontrib>Viitanen, Matti H.</creatorcontrib><creatorcontrib>Jula, Antti M.</creatorcontrib><creatorcontrib>Ekblad, Laura L.</creatorcontrib><title>Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up</title><title>Neurology</title><addtitle>Neurology</addtitle><description>Chronic low-grade inflammation, commonly associated with cardiovascular diseases and risk factors, has been associated inconclusively with cognitive decline and dementia. The aim of our study was to evaluate whether low-grade inflammation, measured in midlife, is associated with a decline in cognitive performance after a 10-year follow-up. We hypothesized that low-grade inflammation, estimated by interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and high-sensitivity CRP (hs-CRP), is a predictor of cognitive decline in the general population.
This prospective cohort study is based on a Finnish nationwide, population-based Health 2000 Examination Survey, its supplemental examinations in 2000-2001, and the follow-up Health 2011 Survey. Cognitive performance at baseline and at follow-up was assessed with categorical verbal fluency (VF), word-list learning (WLL), and word-list delayed recall (WLDR). Baseline low-grade inflammation was measured with IL-6, TNF-α, and hs-CRP in 2001. Associations between low-grade inflammation and cognitive performance were analyzed with multivariable linear models adjusted for age, sex, education,
genotype, type 2 diabetes, hypertension, hypercholesterolemia, body mass index, depressive symptoms, smoking, and baseline cognition.
Nine hundred fifteen participants aged 45-74 years (median age 54 years, 55% women) were included in the analysis. Both higher IL-6 and TNF-α at baseline predicted poorer performance in VF and WLL at 10-year follow-up (VF: IL-6 β: -1.14,
= 0.003, TNF-α β: -1.78,
= 0.008; WLL: IL-6 β: -0.61,
= 0.007, TNF-α β: -0.86,
= 0.03). Elevated IL-6 also predicted a greater decline in VF and WLL after a 10-year follow-up (VF: β: -0.81,
= 0.01; WLL: β: -0.53,
= 0.008). Baseline TNF-α did not predict cognitive decline, and hs-CRP did not predict cognitive performance or decline after 10-years.
Our results suggest that low-grade inflammation in midlife is an independent risk factor for poorer cognitive performance later in life. Of the studied markers, IL-6 and TNF-α seem to be stronger predictors for cognitive performance and decline than hs-CRP.</description><subject>Biomarkers</subject><subject>C-Reactive Protein</subject><subject>Cognition</subject><subject>Diabetes Mellitus, Type 2</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Interleukin-6</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Tumor Necrosis Factor-alpha</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1PGzEQhi3UqgTaf4AqH3sx9cfaXh9R1ABSQjlQBcRh5TizjYt3HexdIv49pnxU6lxGmnnfdzQPQkeMHjPO-PflxfyYvhenjDG1hyZMckWU4Ncf0KSMayJqXe-jg5z_UFqW2nxC-0IxI6uqnqDbk5yj83bwscexxQu_Dr4FfN63wXadHWJ6xAub7iBlvPTDBk_j794P_gHwJaQ2ps72DrAdMKPkBmzCsxhC3JFx-xl9bG3I8OW1H6Jfsx9X0zMy_3l6Pj2ZE1dVRhCplaFcCiO1c4ox6QCo0rBWcrVyujYrBaKFotJUWykYrCmY2hhWQ2toJQ7Rt5fcbYr3I-Sh6Xx2EILtIY654ZozJbSWukirF6lLMecEbbNNvrPpsWG0ecbaFKzN_1iL7evrhXHVwfrd9MbxX-4uhqGgugvjDlKzARuGzd-88lhFOOW8BEpKyoQJ8QRP9YE6</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Kipinoinen, Teemu</creator><creator>Toppala, Sini</creator><creator>Rinne, Juha O.</creator><creator>Viitanen, Matti H.</creator><creator>Jula, Antti M.</creator><creator>Ekblad, Laura L.</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6369-0764</orcidid><orcidid>https://orcid.org/0000-0001-5760-5367</orcidid><orcidid>https://orcid.org/0000-0002-5863-8088</orcidid><orcidid>https://orcid.org/0000-0002-3522-5301</orcidid><orcidid>https://orcid.org/0000-0002-4506-9584</orcidid><orcidid>https://orcid.org/0000-0002-0037-1587</orcidid></search><sort><creationdate>20221115</creationdate><title>Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up</title><author>Kipinoinen, Teemu ; Toppala, Sini ; Rinne, Juha O. ; Viitanen, Matti H. ; Jula, Antti M. ; Ekblad, Laura L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4493-57690253957cc6115cee067ed65bbc789b6e3fe769707a531ed0e989918ef9043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>C-Reactive Protein</topic><topic>Cognition</topic><topic>Diabetes Mellitus, Type 2</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Interleukin-6</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Tumor Necrosis Factor-alpha</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kipinoinen, Teemu</creatorcontrib><creatorcontrib>Toppala, Sini</creatorcontrib><creatorcontrib>Rinne, Juha O.</creatorcontrib><creatorcontrib>Viitanen, Matti H.</creatorcontrib><creatorcontrib>Jula, Antti M.</creatorcontrib><creatorcontrib>Ekblad, Laura L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kipinoinen, Teemu</au><au>Toppala, Sini</au><au>Rinne, Juha O.</au><au>Viitanen, Matti H.</au><au>Jula, Antti M.</au><au>Ekblad, Laura L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2022-11-15</date><risdate>2022</risdate><volume>99</volume><issue>20</issue><spage>e2294</spage><epage>e2302</epage><pages>e2294-e2302</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>Chronic low-grade inflammation, commonly associated with cardiovascular diseases and risk factors, has been associated inconclusively with cognitive decline and dementia. The aim of our study was to evaluate whether low-grade inflammation, measured in midlife, is associated with a decline in cognitive performance after a 10-year follow-up. We hypothesized that low-grade inflammation, estimated by interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and high-sensitivity CRP (hs-CRP), is a predictor of cognitive decline in the general population.
This prospective cohort study is based on a Finnish nationwide, population-based Health 2000 Examination Survey, its supplemental examinations in 2000-2001, and the follow-up Health 2011 Survey. Cognitive performance at baseline and at follow-up was assessed with categorical verbal fluency (VF), word-list learning (WLL), and word-list delayed recall (WLDR). Baseline low-grade inflammation was measured with IL-6, TNF-α, and hs-CRP in 2001. Associations between low-grade inflammation and cognitive performance were analyzed with multivariable linear models adjusted for age, sex, education,
genotype, type 2 diabetes, hypertension, hypercholesterolemia, body mass index, depressive symptoms, smoking, and baseline cognition.
Nine hundred fifteen participants aged 45-74 years (median age 54 years, 55% women) were included in the analysis. Both higher IL-6 and TNF-α at baseline predicted poorer performance in VF and WLL at 10-year follow-up (VF: IL-6 β: -1.14,
= 0.003, TNF-α β: -1.78,
= 0.008; WLL: IL-6 β: -0.61,
= 0.007, TNF-α β: -0.86,
= 0.03). Elevated IL-6 also predicted a greater decline in VF and WLL after a 10-year follow-up (VF: β: -0.81,
= 0.01; WLL: β: -0.53,
= 0.008). Baseline TNF-α did not predict cognitive decline, and hs-CRP did not predict cognitive performance or decline after 10-years.
Our results suggest that low-grade inflammation in midlife is an independent risk factor for poorer cognitive performance later in life. Of the studied markers, IL-6 and TNF-α seem to be stronger predictors for cognitive performance and decline than hs-CRP.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>36195448</pmid><doi>10.1212/WNL.0000000000201116</doi><orcidid>https://orcid.org/0000-0001-6369-0764</orcidid><orcidid>https://orcid.org/0000-0001-5760-5367</orcidid><orcidid>https://orcid.org/0000-0002-5863-8088</orcidid><orcidid>https://orcid.org/0000-0002-3522-5301</orcidid><orcidid>https://orcid.org/0000-0002-4506-9584</orcidid><orcidid>https://orcid.org/0000-0002-0037-1587</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-3878 |
ispartof | Neurology, 2022-11, Vol.99 (20), p.e2294-e2302 |
issn | 0028-3878 1526-632X |
language | eng |
recordid | cdi_proquest_miscellaneous_2721637757 |
source | MEDLINE; Alma/SFX Local Collection; Journals@Ovid Complete |
subjects | Biomarkers C-Reactive Protein Cognition Diabetes Mellitus, Type 2 Female Follow-Up Studies Humans Inflammation Interleukin-6 Male Middle Aged Prospective Studies Tumor Necrosis Factor-alpha |
title | Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T07%3A54%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20Midlife%20Inflammatory%20Markers%20With%20Cognitive%20Performance%20at%2010-Year%20Follow-up&rft.jtitle=Neurology&rft.au=Kipinoinen,%20Teemu&rft.date=2022-11-15&rft.volume=99&rft.issue=20&rft.spage=e2294&rft.epage=e2302&rft.pages=e2294-e2302&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000201116&rft_dat=%3Cproquest_cross%3E2721637757%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2721637757&rft_id=info:pmid/36195448&rfr_iscdi=true |